Antiviral effect of a derivative of isonicotinic acid enisamium iodide (FAV00A) against influenza virus

17Citations
Citations of this article
18Readers
Mendeley users who have this article in their library.

Abstract

With only a single class of antiviral drugs existing for treatment of influenza (neuraminidase inhibitors), the search for novel effective compounds is urgently needed. We evaluated a low molecular mass compound, enisamium iodide (FAV00A), against influenza virus infections in primary differentiated normal human bronchial epithelial (NHBE) cells, and in ferrets. FAV00A (500 μg/ml) markedly inhibited influenza virus replication and reduced viral M-gene expression in NHBE cells. Treatment of ferrets with FAV00A (200 mg/kg once daily for 7 days) initiated 24 h after inoculation with 105 TCID50 of influenza A/Wisconsin/67/2005 (H3N2) virus resulted in a significant decrease in virus titers in the upper respiratory tract. Our data show that FAV00A exhibits an antiviral effect against influenza virus in NHBE cells and provides some benefits in a ferret model. Thus, further evaluation of FAV00A as a potential antiviral agent for treating influenza is warranted.

Cite

CITATION STYLE

APA

Cocking, D., Cinatl, J., Boltz, D. A., Peng, X., Johnson, W., Muzzio, M., … Margitich, V. (2018). Antiviral effect of a derivative of isonicotinic acid enisamium iodide (FAV00A) against influenza virus. Acta Virologica, 62(2), 191–195. https://doi.org/10.4149/av_2018_211

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free